search
Back to results

Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Terminated
Phase
Phase 1
Locations
Sweden
Study Type
Interventional
Intervention
Tadalafil
Sponsored by
Vastra Gotaland Region
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Insulin resistance, Phosphodiesterase-5 inhibition, Microdialysis, Type 2 diabetes, Endothelial dysfunction, Oral hypoglycaemic agents

Eligibility Criteria

40 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Postmenopausal state, defines as natural amenorrhea for at least 12 months.
  2. Age; females 52-65 years, males: 40-65 years.
  3. Type 2 diabetes based on fasting plasma glucose or 2-hr glucose after an OGTT.
  4. Diabetes duration less than 5 years.

Exclusion Criteria:

  1. Patients with concurrent use of nitrates or NO donors, history of heart or cerebrovascular disease, cardiac failure (stages NYHA II-IV), uncontrolled hypertension (> 160/100 mm Hg), significant diabetic complications, and inadequate glycemic control (HbA1c > 7%, ref value 3.5-5.3%)
  2. Patients on glitazones, insulin, beta-blockers, ACE-inhibitors and corticosteroids

Sites / Locations

  • The Wallenberg Laboratory, Dept of Molecular and Clinical Medicine, Sahlgrenska University Hospital, Bruna stråket 16,

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo

Tadalafil

Arm Description

A single dose of placebo is administered 30 min before a mixed meal.

A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.

Outcomes

Primary Outcome Measures

Capillary recruitment, muscle glucose uptake and circulating glucose levels following a meal
Capillary recruitment and glucose uptake in forearm muscle as well as circulating glucose levels following acute administration of tadalafil or placebo in type 2 diabetes patients.

Secondary Outcome Measures

Vascular function and circulating biomarkers.
Arterial stiffness as measured by pulse wave velocity and circulating concentrations of metabolic variables

Full Information

First Posted
October 6, 2010
Last Updated
February 10, 2020
Sponsor
Vastra Gotaland Region
search

1. Study Identification

Unique Protocol Identification Number
NCT01238224
Brief Title
Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes
Official Title
The Effect of Selective PDE-5 Inhibition on Capillary Recruitment, Glucose Uptake and Endothelial Function Following a Mixed Meal in Patients With Type 2 Diabetes Patients.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Terminated
Why Stopped
Durability of study medications could not be guaranteed after the expire date.
Study Start Date
November 2009 (undefined)
Primary Completion Date
November 2011 (Actual)
Study Completion Date
November 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vastra Gotaland Region

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
An increase of blood flow and capillary permeability decrease the impact of an endothelial barrier for glucose and insulin allowing them to reach their target cells in peripheral insulin sensitive organ in the human body. It is well known that insulin-resistant type 2 diabetes patients have an impaired blood flow in skeletal muscle and it is therefore important to elucidate means to reverse this metabolic defect. The investigators have in a recently published study in type 2 diabetes patients used a drug against erectile dysfunction, the PDE-5 inhibitor tadalafil, with known effects on several vascular territories, to increase muscle blood flow in type 2 diabetes patients who were studied after fasting overnight. The aim of this study is to test the hypothesis that tadalafil, compared to placebo, increases muscle glucose uptake and lowers blood glucose following a mixed meal served to type 2 diabetes patients.
Detailed Description
An increase of blood flow and capillary permeability decrease the impact of an endothelial barrier for glucose and insulin allowing them to reach their target cells in peripheral insulin sensitive organ in the human body. It is well known that insulin-resistant type 2 diabetes patients have an impaired blood flow in skeletal muscle and it is therefore important to elucidate means to reverse this metabolic defect. The investigators have in a recently published study in type 2 diabetes patients used a drug against erectile dysfunction, the PDE-5 inhibitor tadalafil, with known effects on several vascular territories, to increase muscle blood flow in type 2 diabetes patients who were studied after fasting overnight. In fact, the investigators observed that tadalafil compared to placebo increased glucose uptake in muscle in parallel with an augmented capillary recruitment in muscle. This was the first publication to show that the pharmacological principle to inhibit the enzyme phosphodiesterase-5 (PDE-5) may mediate an increased muscle glucose uptake and, hence, may be a novel strategy to lower blood glucose in type 2 diabetes patients. The aim of this study is to test the hypothesis that tadalafil, compared to placebo, increases muscle glucose uptake and lowers blood glucose following a mixed meal served to type 2 diabetes patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Insulin resistance, Phosphodiesterase-5 inhibition, Microdialysis, Type 2 diabetes, Endothelial dysfunction, Oral hypoglycaemic agents

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
A single dose of placebo is administered 30 min before a mixed meal.
Arm Title
Tadalafil
Arm Type
Active Comparator
Arm Description
A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.
Intervention Type
Drug
Intervention Name(s)
Tadalafil
Other Intervention Name(s)
Cialis
Intervention Description
This is an acute study. Tadalafil 20 mg administered prior to a meal
Primary Outcome Measure Information:
Title
Capillary recruitment, muscle glucose uptake and circulating glucose levels following a meal
Description
Capillary recruitment and glucose uptake in forearm muscle as well as circulating glucose levels following acute administration of tadalafil or placebo in type 2 diabetes patients.
Time Frame
Five hours after a mixed meal
Secondary Outcome Measure Information:
Title
Vascular function and circulating biomarkers.
Description
Arterial stiffness as measured by pulse wave velocity and circulating concentrations of metabolic variables
Time Frame
Five hours after a mixed meal

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Postmenopausal state, defines as natural amenorrhea for at least 12 months. Age; females 52-65 years, males: 40-65 years. Type 2 diabetes based on fasting plasma glucose or 2-hr glucose after an OGTT. Diabetes duration less than 5 years. Exclusion Criteria: Patients with concurrent use of nitrates or NO donors, history of heart or cerebrovascular disease, cardiac failure (stages NYHA II-IV), uncontrolled hypertension (> 160/100 mm Hg), significant diabetic complications, and inadequate glycemic control (HbA1c > 7%, ref value 3.5-5.3%) Patients on glitazones, insulin, beta-blockers, ACE-inhibitors and corticosteroids
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Per-Anders Jansson, MD, PhD
Organizational Affiliation
Region of Västra Götaland, Sahlgrenska University Hospital/Sahlgrenska University at University of Göteborg, Dept of Molecular and Clinical Medicine, SE 413 45 Göteborg, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Wallenberg Laboratory, Dept of Molecular and Clinical Medicine, Sahlgrenska University Hospital, Bruna stråket 16,
City
Göteborg
ZIP/Postal Code
SE 413 45
Country
Sweden

12. IPD Sharing Statement

Citations:
PubMed Identifier
20535445
Citation
Jansson PA, Murdolo G, Sjogren L, Nystrom B, Sjostrand M, Strindberg L, Lonnroth P. Tadalafil increases muscle capillary recruitment and forearm glucose uptake in women with type 2 diabetes. Diabetologia. 2010 Oct;53(10):2205-8. doi: 10.1007/s00125-010-1819-4. Epub 2010 Jun 10.
Results Reference
background

Learn more about this trial

Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes

We'll reach out to this number within 24 hrs